# Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

> **NCT00398073** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Intraocular Melanoma
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** mouse gp100 plasmid DNA vaccine
- **DEVICE:** The Dermal PowderMed® devices
- **OTHER:** intramuscularly (IM injection)

## Key facts

- **NCT ID:** NCT00398073
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398073, "Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00398073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*